Skip to main content
Top
Published in: Archives of Gynecology and Obstetrics 5/2019

01-11-2019 | Metastasis | Review

Prognostic factors in Krukenberg tumor

Authors: Ruggero Lionetti, Marcello De Luca, Antonio Travaglino, Antonio Raffone, Gabriele Saccone, Antonietta Di Cicco, Luigi Insabato, Massimo Mascolo, Maria D’Armiento, Fulvio Zullo, Francesco Corcione

Published in: Archives of Gynecology and Obstetrics | Issue 5/2019

Login to get access

Abstract

Background

Krukenberg tumor (KT) is a rare secondary ovarian tumor. Little is known about clinicopathologic factors affecting prognosis in KT.

Objective

To assess the prognostic value of clinicopathologic factors in KT through a systematic review and meta-analysis.

Methods

Electronic databases were searched from their inception to February 2019 for studies assessing the association of clinicopathologic factors with overall survival in KT. Pooled hazard ratio (HR) was calculated for each factor; a p value < 0.05 was considered significant.

Results

Twenty-three studies with 1743 patients were included. A decreased overall survival was significantly associated with peritoneal involvement (HR 1.944; p = 0.003), ascites (HR 2.055; p = 0.034), synchronous presentation (HR 1.679; p = 0.034) and increased serum CEA levels (HR 1.380; p = 0.010), but not with age > 50 (HR 0.946; p = 0.743), menopausal status (HR 1.565; p = 0.204), gastric origin (HR 1.600; p = 0.201), size > 5 cm (HR 1.292; p = 0.119), size > 10 cm (HR 0.925; p = 0.714), bilateral ovarian involvement (HR 1.113; p = 0.347), non-peritoneal extaovarian metastases (HR 1.648; p = 0.237), liver metastases (HR 1.118, p = 0.555), predominant signet ring cell morphology (HR 1.322; p = 0.208) and levels of CA125 (HR 0.933; p = 0.828) and CA19.9 (HR 0.996; p = 0.992).

Conclusion

Peritoneal involvement, synchronous presentation, ascites and increased serum CEA levels appear as unfavorable prognostic factors in KT and might affect the patient management.
Appendix
Available only for authorised users
Literature
1.
go back to reference Al-Agha OM, Nicastri AD (2006) An in-depth look at Krukenberg tumor: an overview. Arch Pathol Lab Med 130(11):1725–1730PubMed Al-Agha OM, Nicastri AD (2006) An in-depth look at Krukenberg tumor: an overview. Arch Pathol Lab Med 130(11):1725–1730PubMed
2.
go back to reference Yang C, Sun L, Zhang L et al (2018) Diagnostic utility of SATB2 in metastatic Krukenberg tumors of the ovary: an immunohistochemical study of 70 cases with comparison to CDX2, CK7, CK20, chromogranin, and synaptophysin. Am J Surg Pathol 42(2):160–171PubMedCrossRef Yang C, Sun L, Zhang L et al (2018) Diagnostic utility of SATB2 in metastatic Krukenberg tumors of the ovary: an immunohistochemical study of 70 cases with comparison to CDX2, CK7, CK20, chromogranin, and synaptophysin. Am J Surg Pathol 42(2):160–171PubMedCrossRef
3.
go back to reference Kubeček O, Laco J, Špaček J et al (2017) The pathogenesis, diagnosis, and management metastatic tumors to the ovary: a comprehensive review. Clin Exp Metastasis 34(5):295–307PubMedPubMedCentralCrossRef Kubeček O, Laco J, Špaček J et al (2017) The pathogenesis, diagnosis, and management metastatic tumors to the ovary: a comprehensive review. Clin Exp Metastasis 34(5):295–307PubMedPubMedCentralCrossRef
4.
go back to reference Turan T, Aykan B, Koc S et al (2006) Analysis of metastatic ovarian tumors from extragenital primary sites. Tumori 92(6):491–495PubMedCrossRef Turan T, Aykan B, Koc S et al (2006) Analysis of metastatic ovarian tumors from extragenital primary sites. Tumori 92(6):491–495PubMedCrossRef
5.
go back to reference Kiyokawa T, Young RH, Scully RE (2006) Krukenberg tumors of the ovary: a clinicopathologic analysis of 120 cases with emphasis on their variable pathologic manifestations. Am J Surg Pathol 30(3):277–299PubMedCrossRef Kiyokawa T, Young RH, Scully RE (2006) Krukenberg tumors of the ovary: a clinicopathologic analysis of 120 cases with emphasis on their variable pathologic manifestations. Am J Surg Pathol 30(3):277–299PubMedCrossRef
6.
go back to reference Novak E, Gray LA (1938) Krukenberg tumors of the ovary: clinical and pathological study of 21 cases. Surg Gynecol Obstet 66:157–167 Novak E, Gray LA (1938) Krukenberg tumors of the ovary: clinical and pathological study of 21 cases. Surg Gynecol Obstet 66:157–167
7.
go back to reference Lionetti R, De Luca M, Travaglino A et al (2019) Treatments and overall survival in patients with Krukenberg tumor. Arch Gynecol Obstet 300(1):15–23PubMedCrossRef Lionetti R, De Luca M, Travaglino A et al (2019) Treatments and overall survival in patients with Krukenberg tumor. Arch Gynecol Obstet 300(1):15–23PubMedCrossRef
8.
go back to reference Travaglino A, Raffone A, Saccone G et al (2018) Loss of B-cell lymphoma 2 immunohistochemical expression in endometrial hyperplasia: a specific marker of precancer and novel indication for treatment: A systematic review and meta-analysis. Acta Obstet Gynecol Scand 97(12):1415–1426PubMedCrossRef Travaglino A, Raffone A, Saccone G et al (2018) Loss of B-cell lymphoma 2 immunohistochemical expression in endometrial hyperplasia: a specific marker of precancer and novel indication for treatment: A systematic review and meta-analysis. Acta Obstet Gynecol Scand 97(12):1415–1426PubMedCrossRef
9.
go back to reference Travaglino A, Raffone A, Saccone G et al (2019) Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology 74(5):676–687PubMedCrossRef Travaglino A, Raffone A, Saccone G et al (2019) Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology 74(5):676–687PubMedCrossRef
10.
go back to reference Raffone A, Travaglino A, Saccone G et al (2019) PAX2 in endometrial carcinogenesis and in differential diagnosis of endometrial hyperplasia. A systematic review and meta-analysis of diagnostic accuracy. Acta Obstet Gynecol Scand 98(3):287–299PubMedCrossRef Raffone A, Travaglino A, Saccone G et al (2019) PAX2 in endometrial carcinogenesis and in differential diagnosis of endometrial hyperplasia. A systematic review and meta-analysis of diagnostic accuracy. Acta Obstet Gynecol Scand 98(3):287–299PubMedCrossRef
11.
go back to reference Raffone A, Travaglino A, Saccone G et al (2019) Loss of PTEN expression as diagnostic marker of endometrial precancer: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 98(3):275–286PubMedCrossRef Raffone A, Travaglino A, Saccone G et al (2019) Loss of PTEN expression as diagnostic marker of endometrial precancer: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 98(3):275–286PubMedCrossRef
12.
go back to reference Moher D, Shamseer L, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1PubMedPubMedCentralCrossRef Moher D, Shamseer L, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1PubMedPubMedCentralCrossRef
13.
go back to reference Travaglino A, Raffone A, Saccone G et al (2018) PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 231:104–110PubMedCrossRef Travaglino A, Raffone A, Saccone G et al (2018) PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 231:104–110PubMedCrossRef
14.
go back to reference Raffone A, Travaglino A, Saccone G et al (2019) Management of women with atypical polypoid adenomyoma of the uterus: a quantitative systematic review. Acta Obstet Gynecol Scand 98(7):842–855PubMedCrossRef Raffone A, Travaglino A, Saccone G et al (2019) Management of women with atypical polypoid adenomyoma of the uterus: a quantitative systematic review. Acta Obstet Gynecol Scand 98(7):842–855PubMedCrossRef
16.
go back to reference Slim K, Nini E, Forestier D et al (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73(9):712–716PubMedCrossRef Slim K, Nini E, Forestier D et al (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73(9):712–716PubMedCrossRef
17.
go back to reference Travaglino A, Raffone A, Saccone G et al (2019) Immunohistochemical nuclear expression of β-catenin as a surrogate of CTNNB1 exon 3 mutation in endometrial cancer. Am J Clin Pathol 151(5):529–538PubMedCrossRef Travaglino A, Raffone A, Saccone G et al (2019) Immunohistochemical nuclear expression of β-catenin as a surrogate of CTNNB1 exon 3 mutation in endometrial cancer. Am J Clin Pathol 151(5):529–538PubMedCrossRef
18.
go back to reference Raffone A, Travaglino A, Saccone G et al (2019) Should progesterone and estrogens receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis. Acta Obstet Gynecol Scand 98(8):976–987PubMedCrossRef Raffone A, Travaglino A, Saccone G et al (2019) Should progesterone and estrogens receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis. Acta Obstet Gynecol Scand 98(8):976–987PubMedCrossRef
19.
go back to reference Travaglino A, Raffone A, Saccone G et al (2019) Complexity of glandular architecture should be reconsidered in the classification and management of endometrial hyperplasia. APMIS 127(6):427–434PubMedCrossRef Travaglino A, Raffone A, Saccone G et al (2019) Complexity of glandular architecture should be reconsidered in the classification and management of endometrial hyperplasia. APMIS 127(6):427–434PubMedCrossRef
20.
go back to reference Travaglino A, Raffone A, Saccone G et al (2019) PTEN immunohistochemistry in endometrial hyperplasia: which are the optimal criteria for the diagnosis of precancer? APMIS 127(4):161–169PubMedCrossRef Travaglino A, Raffone A, Saccone G et al (2019) PTEN immunohistochemistry in endometrial hyperplasia: which are the optimal criteria for the diagnosis of precancer? APMIS 127(4):161–169PubMedCrossRef
21.
go back to reference Raffone A, Travaglino A, Saccone G et al (2019) Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis. Arch Gynecol Obstet 299(5):1233–1242PubMedCrossRef Raffone A, Travaglino A, Saccone G et al (2019) Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis. Arch Gynecol Obstet 299(5):1233–1242PubMedCrossRef
22.
go back to reference Raffone A, Travaglino A, Saccone G et al (2019) PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis. Arch Gynecol Obstet 299(6):1511–1524PubMedCrossRef Raffone A, Travaglino A, Saccone G et al (2019) PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis. Arch Gynecol Obstet 299(6):1511–1524PubMedCrossRef
24.
go back to reference Raffone A, Travaglino A, Saccone G et al (2019) Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer. APMIS 127(9):597–606PubMedCrossRef Raffone A, Travaglino A, Saccone G et al (2019) Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer. APMIS 127(9):597–606PubMedCrossRef
27.
go back to reference Rayson D, Bouttell E, Whiston F, Stitt L (2000) Outcome after ovarian/adnexal metastectomy in metastatic colorectal carcinoma. J Surg Oncol 75(3):186–192PubMedCrossRef Rayson D, Bouttell E, Whiston F, Stitt L (2000) Outcome after ovarian/adnexal metastectomy in metastatic colorectal carcinoma. J Surg Oncol 75(3):186–192PubMedCrossRef
28.
go back to reference Kim HK, Heo DS, Bang YJ, Kim NK (2001) Prognostic factors of Krukenberg's tumor. Gynecol Oncol 82(1):105–109PubMedCrossRef Kim HK, Heo DS, Bang YJ, Kim NK (2001) Prognostic factors of Krukenberg's tumor. Gynecol Oncol 82(1):105–109PubMedCrossRef
29.
go back to reference Cheong JH, Hyung WJ, Chen J, Kim J, Choi SH, Noh SH (2004) Surgical management and outcome of metachronous Krukenberg tumors from gastric cancer. J Surg Oncol 87(1):39–45PubMedCrossRef Cheong JH, Hyung WJ, Chen J, Kim J, Choi SH, Noh SH (2004) Surgical management and outcome of metachronous Krukenberg tumors from gastric cancer. J Surg Oncol 87(1):39–45PubMedCrossRef
30.
go back to reference McCormick CC, Giuntoli RL 2nd, Gardner GJ et al (2007) The role of cytoreductive surgery for colon cancer metastatic to the ovary. Gynecol Oncol 105(3):791–795PubMedCrossRef McCormick CC, Giuntoli RL 2nd, Gardner GJ et al (2007) The role of cytoreductive surgery for colon cancer metastatic to the ovary. Gynecol Oncol 105(3):791–795PubMedCrossRef
31.
go back to reference Yook JH, Oh ST, Kim BS (2007) Clinical prognostic factors for ovarian metastasis in women with gastric cancer. Hepatogastroenterology 54(75):955–959PubMed Yook JH, Oh ST, Kim BS (2007) Clinical prognostic factors for ovarian metastasis in women with gastric cancer. Hepatogastroenterology 54(75):955–959PubMed
32.
go back to reference Jiang R, Tang J, Cheng X, Zang RY (2009) Surgical treatment for patients with different origins of Krukenberg tumors: outcomes and prognostic factors. Eur J Surg Oncol 35(1):92–97PubMedCrossRef Jiang R, Tang J, Cheng X, Zang RY (2009) Surgical treatment for patients with different origins of Krukenberg tumors: outcomes and prognostic factors. Eur J Surg Oncol 35(1):92–97PubMedCrossRef
33.
go back to reference Kim WY, Kim TJ, Kim SE et al (2010) The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries. Eur J Obstet Gynecol Reprod Biol 149(1):97–101PubMedCrossRef Kim WY, Kim TJ, Kim SE et al (2010) The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries. Eur J Obstet Gynecol Reprod Biol 149(1):97–101PubMedCrossRef
35.
go back to reference Ojo J, De Silva S, Han E et al (2011) Krukenberg tumors from colorectal cancer: presentation, treatment and outcomes. Am Surg 77(10):1381–1385PubMed Ojo J, De Silva S, Han E et al (2011) Krukenberg tumors from colorectal cancer: presentation, treatment and outcomes. Am Surg 77(10):1381–1385PubMed
36.
go back to reference Guzel AB, Kucukgoz G, Paydas S et al (2012) Preoperative evaluation, clinical characteristics and prognostic factors of nongenital metastatic ovarian tumors: review of 48 patients. Eur J Gynaec Oncol 33(5):493–497 Guzel AB, Kucukgoz G, Paydas S et al (2012) Preoperative evaluation, clinical characteristics and prognostic factors of nongenital metastatic ovarian tumors: review of 48 patients. Eur J Gynaec Oncol 33(5):493–497
37.
go back to reference Lu LC, Shao YY, Hsu CH et al (2012) Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer. Anticancer Res 32(8):3397–3401PubMed Lu LC, Shao YY, Hsu CH et al (2012) Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer. Anticancer Res 32(8):3397–3401PubMed
38.
go back to reference Peng W, Hua RX, Jiang R, Ren C, Jia YN, Li J, Guo WJ (2013) Surgical treatment for patients with Krukenberg tumor of stomach origin: clinical outcome and prognostic factors analysis. PLoS ONE 8(7):e68227PubMedPubMedCentralCrossRef Peng W, Hua RX, Jiang R, Ren C, Jia YN, Li J, Guo WJ (2013) Surgical treatment for patients with Krukenberg tumor of stomach origin: clinical outcome and prognostic factors analysis. PLoS ONE 8(7):e68227PubMedPubMedCentralCrossRef
39.
go back to reference Wu XJ, Yuan P, Li ZY et al (2013) Cytoreductive surgery and hypertermic intraperitoneal chemotherapy improves the survival of gastric cancer patients with ovarian metastasis and peritoneal dissemination. Tumour Biol 34(1):463–469PubMedCrossRef Wu XJ, Yuan P, Li ZY et al (2013) Cytoreductive surgery and hypertermic intraperitoneal chemotherapy improves the survival of gastric cancer patients with ovarian metastasis and peritoneal dissemination. Tumour Biol 34(1):463–469PubMedCrossRef
40.
go back to reference Cho JH, Lim JY, Choi AR et al (2015) Comparison of surgery plus chemotherapy and palliative chemotherapy alone for advanced gastric cancer with krukenberg tumor. Cancer Res Treat 47(4):697–705PubMedCrossRef Cho JH, Lim JY, Choi AR et al (2015) Comparison of surgery plus chemotherapy and palliative chemotherapy alone for advanced gastric cancer with krukenberg tumor. Cancer Res Treat 47(4):697–705PubMedCrossRef
41.
43.
go back to reference Rosa F, Marrelli D, Morgagni P et al (2016) Krukenberg tumors of gastric origin: the rationale of surgical resection and perioperative treatments in a multicenter western experience. World J Surg 40(4):921–928PubMedCrossRef Rosa F, Marrelli D, Morgagni P et al (2016) Krukenberg tumors of gastric origin: the rationale of surgical resection and perioperative treatments in a multicenter western experience. World J Surg 40(4):921–928PubMedCrossRef
44.
go back to reference Ganesh K, Shah RH, Vakiani E et al (2017) Clinical and genetic determinants of ovarian metastases from colorectal cancer. 123(7):1134–1143PubMedCrossRef Ganesh K, Shah RH, Vakiani E et al (2017) Clinical and genetic determinants of ovarian metastases from colorectal cancer. 123(7):1134–1143PubMedCrossRef
45.
go back to reference Kammar PS, Engineer R, Patil PS, Ostwal V, Shylasree TS, Saklani AP (2017) Ovarian metastases of colorectal origin: treatment patterns and factors affecting outcomes. Indian J Surg Oncol 8(4):519–526PubMedPubMedCentralCrossRef Kammar PS, Engineer R, Patil PS, Ostwal V, Shylasree TS, Saklani AP (2017) Ovarian metastases of colorectal origin: treatment patterns and factors affecting outcomes. Indian J Surg Oncol 8(4):519–526PubMedPubMedCentralCrossRef
46.
go back to reference Xu KY, Gao H, Lian ZJ, Ding L, Li M, Gu J (2017) Clinical analysis of Krukenberg tumours in patients with colorectal cancer—a review of 57 cases. World J Surg Oncol 15(1):25PubMedPubMedCentralCrossRef Xu KY, Gao H, Lian ZJ, Ding L, Li M, Gu J (2017) Clinical analysis of Krukenberg tumours in patients with colorectal cancer—a review of 57 cases. World J Surg Oncol 15(1):25PubMedPubMedCentralCrossRef
47.
go back to reference Yu P, Huang L, Cheng G et al (2017) Treatment strategy and prognostic factors for Krukenberg tumors of gastric origin: report of a 10-year single-center experience from China. Oncotarget 8(47):82558–82570PubMedPubMedCentral Yu P, Huang L, Cheng G et al (2017) Treatment strategy and prognostic factors for Krukenberg tumors of gastric origin: report of a 10-year single-center experience from China. Oncotarget 8(47):82558–82570PubMedPubMedCentral
48.
go back to reference Seow-En I, Hwarng G, Tan GHC, Ho LML, Teo MCC (2018) Palliative surgery for Krukenberg tumors—12-year experience and review of the literature. World J Clin Oncol 9(1):13–19PubMedPubMedCentralCrossRef Seow-En I, Hwarng G, Tan GHC, Ho LML, Teo MCC (2018) Palliative surgery for Krukenberg tumors—12-year experience and review of the literature. World J Clin Oncol 9(1):13–19PubMedPubMedCentralCrossRef
49.
go back to reference Tai H, Yang Q, Wu Z et al (2018) PD-L1 expression predicts a distinct prognosis in Krukenberg tumor with corresponding origins. J Immunol Res 2018:9485285PubMedPubMedCentral Tai H, Yang Q, Wu Z et al (2018) PD-L1 expression predicts a distinct prognosis in Krukenberg tumor with corresponding origins. J Immunol Res 2018:9485285PubMedPubMedCentral
Metadata
Title
Prognostic factors in Krukenberg tumor
Authors
Ruggero Lionetti
Marcello De Luca
Antonio Travaglino
Antonio Raffone
Gabriele Saccone
Antonietta Di Cicco
Luigi Insabato
Massimo Mascolo
Maria D’Armiento
Fulvio Zullo
Francesco Corcione
Publication date
01-11-2019
Publisher
Springer Berlin Heidelberg
Published in
Archives of Gynecology and Obstetrics / Issue 5/2019
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-019-05301-x

Other articles of this Issue 5/2019

Archives of Gynecology and Obstetrics 5/2019 Go to the issue